Investment
Features
FeesSafety
Academy
More
Pluang+

Compare US Global Jets ETF (JETS) vs GeneDx Holdings Corp (WGS) Price & Performance

US Global Jets ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

US Global Jets ETF vs GeneDx Holdings Corp — how do they compare? US Global Jets ETF trades at $30.51, while GeneDx Holdings Corp trades at $60.71 (market cap $1.80B). The key difference: US Global Jets ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

JETSWGS
Sector
Sector/ThematicTechnology
52-Week High
$33.34$167.51
52-Week Low
$23.12$34.51
Market Cap
$1.80B
Enterprise Value
$1.80B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

US Global Jets ETF

JETS trades at $30.58, up 0.39% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF faces headwinds from rising fuel costs as U.S. airlines spent $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, July 2026), though falling oil prices recently provided some relief. Technical indicators show RSI levels in oversold territory at 24.66 for the 12-day period, suggesting potential buying opportunity.

The outlook remains cautious as airline profits face pressure from fuel volatility and Middle East conflict impacts. While lower oil prices offer temporary relief, the sector's cyclical nature and competitive dynamics with defense-focused ETFs present ongoing challenges. Investment opportunity exists for those betting on travel recovery, but risks from fuel price shocks and operational disruptions require careful monitoring.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.

Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.

Returns comparison

Trailing returns across standard periods

About US Global Jets ETF

JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.

Read more on JETS

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS